REG - Futura Medical PLC - Notice of AGM & availability of Annual Report

Futura MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD9114Ga&default-theme=true

RNS Number : 9114G  Futura Medical PLC  04 June 2026

4 June 2026

Futura Medical plc

("Futura", "the Group" or the "Company")

Notice of AGM & Availability of Annual Report

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that
specialises in the development and global commercialisation of innovative and
clinically proven sexual health products, today announces its Annual General
Meeting ("AGM") will be held at 10:00am on Monday, 29 June 2026 at the offices
of Panmure Liberum, Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.

If you wish to attend the meeting in person, please register your interest at
investor.relations@futuramedical.com.

Shareholders are asked to cast their vote as follows: (1) casting your proxy
vote online via the Investor Centre app or by accessing the web browser at
https://uk.investorcentre.mpms.mufg.com/
(https://uk.investorcentre.mpms.mufg.com/) and following the instructions; or
(2) in the case of CREST members, by utilising the CREST electronic proxy
appointment service; or (3) if you are an institutional investor you may also
be able to appoint a proxy electronically via the Proxymity platform; or (4)
requesting a hard copy form of proxy directly from the Registrars, MUFG
Corporate Markets. For further information, please refer to the notes to the
Notice of Annual General Meeting. If you choose to attend the Annual General
Meeting in person instead of appointing the Chairman of the meeting as proxy,
you will still be able to vote in person at the Annual General Meeting.

If you are not attending the Annual General Meeting in person, your proxy vote
will need to be logged by 10:00am on Thursday, 25 June 2026, as no online
voting will take place in-real time during the meeting itself.

 

Annual Report

Futura's annual report and accounts for the year ended 31 December 2025 (the
"Annual Report") is available to shareholders as an electronic communication
pursuant to the Companies Act 2006 and is now available on the Company's
website www.futuramedical.com (http://www.futuramedical.com) , along with the
Notice of AGM.

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters        +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative,
consumer-focused, sexual health products, including lead product
Eroxon(®) and development projects WSD4000 and Eroxon(®) Intense. Our core
strength lies in our research, development, regulatory and business
development expertise in developing innovative, clinically proven, insight-led
and effective products to support our customers in the growing sexual health
market.

Sexual health issues are prevalent globally in both men and women. Erectile
Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets,
with approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. 60% of women experience at least one symptom
of impaired sexual response or function in a twelve months period, with only
one in four women seeking professional help and remaining chronically
underserved.

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection fast, addresses significant unmet needs in the ED market. Multiple
license or distribution partnerships are in place for Eroxon(®), across major
consumer markets.

WSD4000 is a project name for our development female sexual health portfolio,
starting with the creation of a range of topical gels under our unique
platform technology, specifically designed to treat symptoms of sexual
dysfunction in women. There is currently no known regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal, lubrication and ability to orgasm.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASSWFWDEMSEFM



            Copyright 2019 Regulatory News Service, all rights reserved